These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9849317)

  • 1. Correlation of 9G4 idiotope with disease activity in patients with systemic lupus erythematosus.
    Isenberg DA; McClure C; Farewell V; Spellerberg M; Williams W; Cambridge G; Stevenson F
    Ann Rheum Dis; 1998 Sep; 57(9):566-70. PubMed ID: 9849317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
    Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
    Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study.
    Ravirajan CT; Rowse L; MacGowan JR; Isenberg DA
    Rheumatology (Oxford); 2001 Dec; 40(12):1405-12. PubMed ID: 11752513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in Systemic Lupus Erythematosus.
    Mora C; Medina-Rosas J; Santos AM; Jaimes DA; Arbeláez AM; Romero C; Cortes A; Londono J
    J Rheumatol; 2016 Sep; 43(9):1657-64. PubMed ID: 27134246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the 9G4 idiotope in systemic lupus erythematosus.
    Isenberg D; Spellerberg M; Williams W; Griffiths M; Stevenson F
    Br J Rheumatol; 1993 Oct; 32(10):876-82. PubMed ID: 7691367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus.
    Atta MS; Lim KL; Ala'deen DA; Powell RJ; Todd I
    Ann Rheum Dis; 1995 Feb; 54(2):117-24. PubMed ID: 7702398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.
    Ho A; Magder LS; Barr SG; Petri M
    Arthritis Rheum; 2001 Oct; 44(10):2342-9. PubMed ID: 11665975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 9G4+ autoantibodies are an important source of apoptotic cell reactivity associated with high levels of disease activity in systemic lupus erythematosus.
    Jenks SA; Palmer EM; Marin EY; Hartson L; Chida AS; Richardson C; Sanz I
    Arthritis Rheum; 2013 Dec; 65(12):3165-75. PubMed ID: 23983101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of the VH4-21 gene segment by anti-DNA antibodies from patients with systemic lupus erythematosus.
    Stevenson FK; Longhurst C; Chapman CJ; Ehrenstein M; Spellerberg MB; Hamblin TJ; Ravirajan CT; Latchman D; Isenberg D
    J Autoimmun; 1993 Dec; 6(6):809-25. PubMed ID: 8155258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic.
    Nasiri S; Karimifar M; Bonakdar ZS; Salesi M
    Rheumatol Int; 2010 Nov; 30(12):1605-9. PubMed ID: 19809816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.
    Lim KL; Jones AC; Brown NS; Powell RJ
    Ann Rheum Dis; 1993 Jun; 52(6):429-35. PubMed ID: 8323394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity.
    Zandman-Goddard G; Blank M; Langevitz P; Slutsky L; Pras M; Levy Y; Shovman O; Witte T; Doria A; Rovensky J; Shoenfeld Y
    Ann Rheum Dis; 2005 Dec; 64(12):1698-702. PubMed ID: 16014675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-beta2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome.
    Inanç M; Donohoe S; Ravirajan CT; Radway-Bright EL; Mackie I; Machin S; Isenberg DA
    Br J Rheumatol; 1998 Oct; 37(10):1089-94. PubMed ID: 9825748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q.
    Mok CC; Birmingham DJ; Ho LY; Hebert LA; Song H; Rovin BH
    Lupus; 2012 Jan; 21(1):36-42. PubMed ID: 21993384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and clinico-serological correlations of anti-alpha-enolase, anti-C1q, and anti-dsDNA antibodies in patients with systemic lupus erythematosus.
    Mosca M; Chimenti D; Pratesi F; Baldini C; Anzilotti C; Bombardieri S; Migliorini P
    J Rheumatol; 2006 Apr; 33(4):695-7. PubMed ID: 16583471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3.
    Flechsig A; Rose T; Barkhudarova F; Strauss R; Klotsche J; Dähnrich C; Schlumberger W; Enghard P; Burmester GR; Hiepe F; Biesen R
    Clin Exp Rheumatol; 2017; 35(4):598-606. PubMed ID: 28281463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.
    Yee CS; Farewell V; Isenberg DA; Rahman A; Teh LS; Griffiths B; Bruce IN; Ahmad Y; Prabu A; Akil M; McHugh N; D'Cruz D; Khamashta MA; Maddison P; Gordon C
    Arthritis Rheum; 2007 Dec; 56(12):4113-9. PubMed ID: 18050213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic idiotypes of autoantibodies in autoimmunity: lessons from new experimental models of SLE.
    Shoenfeld Y; Mozes E
    FASEB J; 1990 Jun; 4(9):2646-51. PubMed ID: 2140806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of 13 autoantibodies and of the 16/6 and related pathogenic idiotypes in 465 patients with systemic lupus erythematosus and their relationship with disease activity.
    Villarreal GM; Drenkard C; Villa AR; Slor H; Shafrir S; Bakimer R; Shoenfeld Y; Alarcón-Segovia D
    Lupus; 1997; 6(5):425-35. PubMed ID: 9229360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.